OVERVIEW

Achieving Treat-to-Target Goals in Systemic Lupus Erythematosus (SLE) is organized by Postgraduate Institute for Medicine (PIM), RedMedEd.

Dates:
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/8/2021 through 1/8/2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

Target Audience:
This activity is intended for rheumatologists and other health care providers involved in the care of patients with SLE.

Accreditation:
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 ABIM Maintenance of Certification Part 2 credit MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Activity Description:
Because of its varied, changing, and sometimes subtle manifestations, systemic lupus erythematosus (SLE) is notably difficult to manage. It is thus essential to ensure that, once an SLE diagnosis has been established, disease activity measures are applied consistently and uniformly. Because SLE is associated with cumulative permanent organ damage that leads to significant morbidity and mortality, treatment should aim to prevent organ damage and to optimize health-related quality-of-life by controlling disease activity and minimizing comorbidities and drug toxicity.

In this activity, learners will meet two patients: Amy, a new mother with a history of SLE who has been experiencing foot and ankle swelling, and Maria, a teenage girl with left knee swelling. The activity examines strategies for monitoring SLE disease activity and damage, as well as guideline-driven recommendations for treating SLE and managing treatment side effects to optimize patient outcomes.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Define SLE disease activity and utilize disease activity indices to recognize exacerbations (flares)
• Employ regular long-term monitoring and review and/or adjust therapy for patients who have SLE, as needed
• Integrate understanding of damage associated with SLE into clinical decision-making
• Describe the relationship between corticosteroids, disease activity, and organ damage
• Discuss the current understanding of SLE pathophysiology and use this knowledge to compare and select treatments